PRESS RELEASE. Capitainer, a Swedish MedTech company supplying reliable solutions for self-sampling of blood and plasma, has raised a further SEK 34 million with Sciety and its investment syndicate in a new share issue. The company will use the proceeds to fund additional product validations, sales, and marketing to meet
NEW COMPANY AT SCIETY. Long waiting time for surgery, deficiencies in patient safety, and high costs for care related to surgery. Healthcare faces significant challenges in Sweden and internationally while the demands for quality-improving measures are increasing. A Swedish health-tech player with an IT solution implementing structure and systematics in
PRESS RELEASE. Sciety recently made an investment of over SEK 58 million in the cell therapy company NEOGAP Therapeutics, which is developing personalised immunotherapy for the treatment of cancer. The new capital will be used for a clinical phase I/II trial in colorectal cancer with an estimated start in 2022.
PRESS RELEASE. The Swedish biotechnology company Synartro, which is developing a novel, improved treatment for knee osteoarthritis, has successfully raised SEK 34 million with Sciety and its investment syndicate. The new capital will be used for the company’s first clinical trial expected to start in 2022. ”We greatly appreciate the
PRESS RELEASE. The Swedish diagnostics company SAGA Diagnostics, which develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment, recently completed a share issue of SEK 106 million led by Segulah Medical Acceleration together with Sciety. Hadean Ventures, which invested in the company at an
NEW COMPANY AT SCIETY. Osteoarthritis affects more than 320 million people globally and is a leading source of chronic pain and disability in Europe and the US. Only half of the patients receive adequate pain relief. Sciety is now financing a company whose drug candidate has the potential to provide